IMBIORAY's ACC-NK Antibody-Cell Conjugated NK

ACC-NK (Antibody-Cell Conjugated NK) integrates the antigen-targeting function of antibodies with the immune-killing function of NK cells through antibody conjugation technology (non-viral vector, non-gene editing). By using antibodies to target specific tumor antigens, ACC-NK can rapidly and efficiently guide NK cells to recognize and kill tumor cells.

Ongoing Clinical Programs

• Postoperative tumor recurrence prevention

• Solid tumor treatment

• Warburg effect combined with NK therapy for advanced solid tumors

• Proton and heavy ion therapy combined with NK therapy for solid tumors

ACC-NK (ACC-NK854)

An ACC-NK Cell Product Targeting 5T4 for Solid Tumor Treatment, Entering Registered Clinical Phase II

Trophoblast glycoprotein (5T4) is an N-glycosylated transmembrane protein involved in the immune privilege of embryonic cells. It is highly expressed in embryonic trophoblast cells and present in over 90% of solid tumors. 5T4 is already expressed in precancerous lesions (e.g., colonic polyps, pulmonary nodules). ACC-NK854 enables early elimination to block the progression of carcinogenesis.

ACC-NK (ACC-NK822)

A first-in-class ACC-NK cell product targeting Trop-2 for solid tumors, in registrational clinical stage

Imbioray’s ACC-NK cell therapy targeting Trop-2 is a globally innovative therapy with tremendous potential in immuno-oncology (IO) and antibody-drug conjugate (ADC) applications. It overcomes the high toxicity and narrow therapeutic window of Trop-2-targeted ADCs, offering a novel treatment paradigm. Combined with ADCs, radiotherapy, and chemotherapy, it reduces side effects, significantly enhances efficacy, and prolongs patient survival.

ACC-NK (ACC-NK733)

An ACC-NK cell product targeting CD33-CLL1 dual epitopes for hematological malignancies, in registrational clinical stage

This first-in-class CD33-CLL1 dual-targeting therapy kills both AML cells and leukemia stem cells, demonstrating significant efficacy in controlling and improving advanced hematological malignancies.

ACC-NK Combination Therapy

Combining ACC-NK cell therapy with conventional treatments produces synergistic effects: boosting immunity in tumor patients, lowering risks and toxicities of standard therapies, effectively clearing circulating tumor cells in the blood, and reducing tumor recurrence and metastasis. It activates the body’s immune system to enhance anti-tumor activity, achieving a 1+1>2 effect.

子、重离子疗法联合NK治疗实体瘤